rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    EQ
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      Raymond James reiterates Strong Buy on Equillium stock at $7 target
      Nov 13Investing.comEQRJF
      Jefferies reiterates Equillium stock rating on clinical progress
      Nov 13Investing.comEQ
      Equillium Reports Third Quarter 2026 Financial Results and Recent Corporate and Clinical Highlights
      Nov 12Yahoo FinanceEQ
      Equillium to Participate in Upcoming Investor Conferences
      Nov 5Yahoo FinanceEQ
      Equillium doses first patient in EQ504 phase 1 trial
      Oct 26Investing.comEQ
      Analysts’ Top Healthcare Picks: Equillium (EQ), NeoGenomics (NEO)

      Detailed price information for Neogenomics Inc (NEO-Q) from The Globe and Mail including charting and trades.

      Oct 7The Globe and MailEQNEO
      Equillium Advances EQ504 With Phase 1 Trial Clearance

      Detailed price information for Equillium Inc (EQ-Q) from The Globe and Mail including charting and trades.

      Oct 6The Globe and MailEQ
      Equillium stock price target maintained at $20 by Piper Sandler
      Oct 6Investing.comEQPIPR
      Equillium Announces Poster Presentation at the 50th Anniversary La Jolla Immunology Conference
      Oct 6Yahoo FinanceEQ
      Equillium Receives Australian Regulatory Clearance to Initiate First-in-Human Clinical Trial of EQ504

      On track to initiate dosing by early November 2026; topline Phase 1 proof-of-mechanism data anticipated approximately six months following study initiation Randomized, double-blind, placebo-controlled study will evaluate safety, tolerability, pharmacokinetics and pharmacodynamics of EQ504 in healthy subjects LA JOLLA, Calif., Oct. 05, 2026 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders,

      Oct 5Yahoo FinanceEQ
      Equillium Gets Australian Clearance for Phase 1 Trial of Ulcerative Colitis Drug Candidate EQ504
      Oct 5Yahoo FinanceEQ
      Equillium Eyes Q4 Phase I Start for Ulcerative Colitis Drug EQ504
      Sep 27Yahoo FinanceEQ
      Equillium at Stifel 2026 Virtual Immunology and Inflammation Forum: pipeline advances
      Sep 23Investing.comEQSF
      Equillium to Participate in Stifel’s 2026 Virtual Immunology and Inflammation Forum

      LA JOLLA, Calif., Sept. 16, 2026 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders, today announced that management will be participating in a fireside chat at Stifel’s 2026 Virtual Immunology and Inflammation Forum on Wednesday, September 23, 2026 at 12:00pm EDT. Members of the Equillium management team will be available to meet with investors who are registered to attend the conference. A

      Sep 16Yahoo FinanceEQ
      Equillium at Cantor conference: EQ504 advances as lead ahr program
      Sep 11Investing.comEQ
      Equillium to Participate in Upcoming Investor Conferences

      LA JOLLA, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders, today announced that management will participate in the following upcoming investor conferences: Cantor Global Healthcare Conference 2026Format: Fireside Chat & 1x1 MeetingsDate: Wednesday, September 9, 2026Time: 9:45 AM EDTWebcast Link: Here H.C. Wainwright 28th Annual Global Investment ConferenceFormat: Co

      Sep 2Yahoo FinanceEQ

      This is the newest page. Registered accounts read further back.